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The aim of this study was to assess the implications of
insulin resistance on the clinical and biochemical profiles of
Korean type 2 diabetic patients. 122 patients with type 2
diabetes underwent a short insulin tolerance test to assess
insulin resistance. Subjects were classified in tertiles according
to ISI (insulin sensitivity index), and the tertile I (the insulin-
resistant group) and tertile III (the insulin-sensitive group)
clinical and biochemical parameters were compared. Age,
waist circumference (WC), systolic blood pressure (SBP),
HbA1c, body fat content, and fasting plasma glucose were
significantly higher in tertile I than tertile III (all p <0.05). The
frequency of hypertension and family history of cerebro-
vascular disease (CVD) were greater in tertile I than III (p <
0.05). To evaluate the factors affecting ISI, multiple regression
was performed, and age, WC, SBP, HbA1c, and body fat
content were found to be independently related to insulin resis-
tance (p<0.05). Old age, hypertension, central obesity, and
poor glycemic control were identified as clinical parameters of
insulin resistance in Korean type 2 diabetic patients.
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INTRODUCTION
A substantial amount of data indicates that
insulin resistance plays a major role in the devel-
opment of glucose intolerance and type 2 diabetes.
Insulin resistance is a consistent finding in
patients with type 2 diabetes, and resistance is
present years before the onset of diabetes.
1 Pro-
spective studies show that insulin resistance
predicts the onset of diabetes.
2 The term 'insulin
resistance' indicates an impaired biologic response
to either exogenously administered or endoge-
nously secreted insulin. Insulin resistance is mani-
fested by decreased insulin stimulated glucose
transport and metabolism in adipocytes and
skeletal muscle, and by impaired suppression of
hepatic glucose output. Insulin sensitivity is in-
fluenced by a number of factors, including age,
weight, ethnicity, body fat, physical activity, and
medications. It has been reported that insulin
resistance is associated with adiposity, particu-
larly that which is centrally deposited, which is
metabolically more active than that which is
peripherally deposited.
3,4 Insulin resistance is also
associated with hypertension and dyslipidemia
(increased triglyceride and decreased HDL
cholesterol levels) in type 2 diabetic subjects.
4-7
In this study, we compared the clinical and
biochemical characteristics of insulin-sensitive and
insulin-resistant type 2 diabetic subjects, in order
to assess the implications of insulin resistance in
these diabetic patients, and to determine their
clinical and biochemical profiles.
MATERIALS AND METHODS
A total of 122 type 2 diabetic patients at the
Severance Hospital (YUMC) clinic participated in
this study. The study protocol was approved by
the ethical committee of Yonsei University College
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of Medicine. Clinical data and informed consent
were obtained from each patient. BMI (body mass
index) and WC were recorded. Body fat content
was measured by bioelectric impedance meter
(InBody 3.0, Biospace, Korea). Hypertension was
diagnosed if the patient had a blood pressure
greater than 130/85 mmHg or was on antihy-
pertensive therapy at the time of the study. The
diagnosis of nephropathy was made when daily
albumin loss exceeded 300 mg. Retinopathy was
evaluated by fundoscopic examination and by
fluourescein fundus angiography, and neuropathy
was diagnosed with peripheral neuropathy by
nerve conduction velocity. Patients with coronary
disease were documented by angiography or
through a history of angina and acute myocardial
infarction. Patients with CVD were documented
by brain MRI (magnetic resonance imaging) or a
history of stroke. Plasma glucose was measured
using the glucose oxidase technique on an auto-
analyzer (Beckman, Fullerton, CA, USA). HbA1C
was analyzed by high performance liquid chroma-
tography (HPLC) (Variant II, Bio-Rad, Hercules,
CA, USA). Insulin and C-peptide (fasting, post-
prandial) were measured by radioimmunoassay
(Instar, Stillwater, MN, USA). Plasma lipoprotein
measurements were obtained from fasting single
fresh plasma samples using microplate methods
(Behring ELISA Processor II Plus, Marburg, Ger-
many). Total cholesterol and triglyceride concen-
trations were measured using an autochemical
analyzer (Hitachi 747, Nakashi, Japan) and an
enzymatic method (Roche Diagnostics, Basel,
Switzerland). HDL cholesterol was assayed by the
selective inhibition test (Daichii, Tokyo, Japan).
LDL cholesterol was calculated according to the
Friedewald formula. Fibrinogen in citrated plasma
was measured using a modified clot-rate assay
and a Diagnostica Stago STA instrument (Asnieres-
Sur-Serine, France).
8 This technique was based on
the original method of Clauss.
9 Insulin sensitivity
was determined by the short insulin tolerance test
(ITT).
10,11
On the morning of the test day, a 20 G catheter
equipped with a connector for blood sampling
was inserted reversibly into one cephalic vein, and
vessel blockage was prevented by a slow, constant
infusion of saline solution. A second 20 G catheter
was inserted for insulin and glucose infusion.
After the second catheter was inserted, the subject
was asked to lie at rest for 20-30 minutes. In order
to obtain an arterialized vein, the temperature at
the sampling site was maintained at 60-70 with
a heating pad. With the subject at rest, 0.1 U per
kg of body weight of a 100x diluted short-acting
human insulin (Humulin-R, Eli Lilly, Indiana, IN,
USA) was administered via the vein, and a blood
sample was obtained from the opposite vein at 0,
3, 6, 9, 12, and 15 min. Each blood sample was im-
mediately centrifuged and its glucose concentra-
tion determined. The insulin sensitivity index (ISI,
%/min) was derived by linear regression from the
rate of fall of the log glucose value between 3 and
15 min. The t1/2 was calculated when the baseline
blood glucose level reached 50% of its initial value,
and the ISI was calculated from the equation:
ISI=0.693/t1/2 × 100 (%/min)
Patients were classified into tertiles in accor-
dance with ISI (0.39-4.70%/min).
We compared the clinical and biochemical
characteristics of insulin-resistant (Tertile I, mean
ISI=0.98 ± 0.31%/min) and insulin-sensitive sub-
jects (Tertile III, mean ISI=3.50 ± 0.64%/min) by
t-test or χ
2 test (SAS Institute, Cary, NC). Mul-
tiple linear regression was performed to identify
the factors affecting ISI (SAS Institute, Cary, NC).
A p-value less than 0.05 was considered signi-
ficant.
RESULTS
The ISI results ranged from 0.39 to 4.70%/min
(mean ISI=2.14 ± 1.10%/min). According to the
ISI, as measured in the short insulin tolerance test
(ITT), subjects were classified into tertile I (0.39 <
ISI < 1.54%/min; n=40), tertile II (1.54 <ISI < 2.55%/
min; n=42), and tertile III (2.55 < ISI < 4.70%/min;
n=40). The following conclusions were drawn by
comparing the clinical characteristics of insulin-
sensitive (tertile III) and insulin-resistant (tertile I)
subjects. The insulin-resistant group was signifi-
cantly older (57.3 ± 12.7 years vs. 50.0 ± 12.6
years, p < 0.05). They also had a higher prevalence
of hypertension and family history of CVD (37.5%
vs. 20.0% and 22.5% vs 7.5%, respectively, p <
0.05). There was no difference between tertile I
and III in terms of BMI (22.6 ± 3.0 vs. 23.4 ± 3.4Jong-Suk Park, et al.
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kg/m
2, p > 0.05), but WC (84.5 ± 5.3 vs. 82.1 ± 5.1
cm, p < 0.05) and body fat content (28.9 ± 4.3% vs.
27.0 ± 4.0%, p < 0.05) were significantly higher in
the insulin-resistant group (tertile I) than in the
insulin-sensitive group (tertile III). SBP was higher
in tertile I than in tertile III (141.2 ± 22.4 vs. 131.0
± 16.4 mmHg, p < 0.05), but no difference was
found in DBP (88.1 ±12.6 vs. 86.0 ± 8.9 mmHg, p
> 0.05). In addition, no differences were found
between tertiles I and III in terms of sex, onset and
duration of diabetes, smoking, CVD, family his-
tory of hypertension, diabetes, coronary disease or
diabetic microvascular complications, i.e. nephr-
opathy, neuropathy, and retinopathy (Table 1).
Insulin-resistant subjects had a higher fasting
plasma glucose and HbA1c (10.5 ± 4.5 vs. 8.7 ±
3.9 mmol/L, p < 0.05; 9.8 ± 2.2% vs. 7.5 ± 1.8%, p
< 0.05) than insulin-sensitive subjects. However,
no statistically significant differences were found
between tertiles I and III in terms of postprandial
2-hour blood glucose, fasting or postprandial in-
sulin and C-peptide, total cholesterol, triglyceride,
LDL-cholesterol, HDL-cholesterol, or fibrinogen
levels (Table 2). There was no statistical difference
in treatment modality between insulin-resistant
and insulin-sensitive subjects. To evaluate the fac-
tors affecting ISI, multiple regression analysis was
performed after adjusting for HbA1c. Since
HbA1C and insulin resistance (ISI) were highly
correlated ( =-0.39), they were not included in β
the same regression model. The results indicated
that age, WC, SBP and body fat content were
significant independent variables. The correlations
between ISI and age ( =-0.21), WC ( =-0.23), β β
SBP ( =-0.20), and body fat content ( =-0.20) β β
were statistically significant (Table 3), which sug-
gests that WC and body fat content provide a bet-
ter measure of visceral adiposity than does BMI.
DISCUSSION
In this study, differences were found between
the clinical manifestations of type 2 diabetic
Table 1. Clinical Characteristics of Patients
Tertile I (N=40) Tertile III (N=40)
Age (yrs) 57.3 ± 12.7 50.0 ± 12.6*
Sex (M : F) 19 : 21 18 : 22
Onset of diabetes (yrs) 46.1 ± 12.8 42.6 ± 12.0
Duration of diabetes (yrs) 10.9 ± 7.0 7.3 ± 8.5
BMI (kg/m
2) 22.6 ± 3.0 23.4 ± 3.4
WC (cm) 84.5 ± 4.3 82.1 ± 5.1*
Body Fat (%) 28.9 ± 4.3 27.0 ± 4.0*
SBP (mmHg) 141.2 ± 22.4 131.0 ± 16.4*
DBP (mmHg) 88.1 ± 12.6 86.0 ± 8.9
Smoking 12/40 (30.0%) 11/40 (27.5%)
History of CVD 7/40 (17.5%) 6/40 (15.0%)
History of hypertension 15/40 (37.5%) 8/40 (20.0%)
Family history of diabetes 16/40 (40.0%) 15/40 (37.5%)
Family history of hypertension 26/40 (65.0%) 19/40 (47.5%)
Family history of coronary disease 17/40 (42.5%) 21/40 (52.5%)
Family history of CVD 9/40 (22.5%) 3/40 (7.5%)*
Nephropathy 18/40 (45.0%) 14/40 (35.0%)
Neuropathy 16/40 (40.0%) 15/40 (37.5%)
Retinopathy 21/40 (52.5%) 16/40 (40.0%)
Data are means±SD; *p<0.05, p<0.01.
SBP, systolic blood pressure; DBP, diastolic blood pressure; CVD, cerebrovascular disease.Insulin Resistance in Korean Patients with Type 2 Diabetes Mellitus
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patients in accordance with their levels of insulin
resistance. Such differences suggest that insulin
resistance plays an important role in the devel-
opment of clinical manifestations, and in the path-
ogenesis of the disease. A variety of approaches
have been proposed to qualitatively and quantita-
tively describe insulin sensitivity;
12,13 for example,
fasting or postprandial insulin and C-peptide, the
insulin tolerance test (ITT),
14,15 the frequently sam-
pled intravenous glucose tolerance test (FSIVGTT),
16,17 and the euglycemic clamp test.
18 Of these ap-
proaches, insulin concentration, especially fasting
insulin concentration, although commonly used as
a surrogate for insulin resistance,
19,20 may not be
an optimum choice as a surrogate for insulin re-
sistance in type 2 diabetic patients. Insulin secre-
tion decreases with increased hyperglycemia
(g1ucotoxicity), and diabetic subjects have in-
creased levels of proinsulin, which is recognized
by some (but not all) insulin assays.
21 Insulin is
reported to have considerable cross-reactivity with
proinsulin.
19,20,22 While the euglycemic clamp test
is widely regarded as the 'gold standard' for sen-
sitivity measurement, it remains a laboratory pro-
cedure, because it requires sophisticated equip-
ment, highly trained personnel, and is a lengthy
procedure. Thus, there is a need for simpler al-
ternative methods for measuring insulin sensi-
tivity.
17 Although there are limits to the validity
of ITT,
23,24 if it is performed while the blood glu-
Table 2. Biochemical Profiles of Patients
Tertile I (N=40) Tertile III (N=40)
Fasting plasma glucose (mmol/L) 10.5 ± 4.5 8.7 ± 3.9*
Postprandial 2 hour glucose (mmol/L) 16.4 ± 7.3 12.1 ± 6.3
HbA1c (%) 9.8 ± 2.2 7.5 ± 1.8*
Total cholesterol (mmol/L) 5.26 ± 1.14 5.16 ± 0.85
Triglyceride (mmol/L) 1.85 ± 1.08 1.83 ± 1.12
HDL-cholesterol (mmol/L) 1.16 ± 0.27 1.14 ± 1.26
LDL-cholesterol (mmol/L) 3.45 ± 1.16 3.28 ± 1.12
Fibrinogen (mg/dL) 383.1 ± 101.2 378.4 ± 113.1
Fasting insulin (pmol/L) 49.8 ± 42.0 44.4 ± 26.4
Postprandial 2 hour insulin (pmol/L) 133.2 ± 96.6 126.6 ± 105.6
Fasting C-peptide (nmol/L) 0.46 ± 0.23 0.53 ± 0.23
Postprandial 2 hour C-peptide (nmol/L) 0.86 ± 0.53 1.06 ± 0.50
Data are means±SD; *p<0.05.
Table 3. Factors Affecting Insulin Resistance (ISI)
β β
HbA1c (%) -0.39* T. cholesterol (mmol/L) -0.35
Age (yrs) -0.21* TG (mmol/L) -0.59
IBW (%) -0.10 HDL-C (mmol/L) -0.01
BMI (kg/m
2) -0.11 LDL-C (mmol/L) -0.01
WC (cm) -0.23* Insulin (fasting) (pmol/L) -0.04
Fat (%) -0.20* Insulin (postprandial 2 hour) (pmol/L) -0.17
SBP (mmHg) -0.20* C-peptide (fasting) (nmol/L) -0.01
DBP (mmHg) -0.14 C-peptide (postprandial 2 hour) (nmol/L) 0.03
Data are means ± SD, *p < 0.05.
IBW (%), percentage of ideal body weight; Fat (%), percentage of body fat content; SBP, systolic blood pressure;
DBP, diastolic blood pressure; HDL-C, HDL-cholesterol; LDL-C, LDL-cholesterol.Jong-Suk Park, et al.
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cose level is stable (subjects with a fasting glucose
level < 7.8 mmol/L), then it is a valid measure of
insulin resistance, as compared to the hyperinsu-
linemic-euglycemic clamp test.
10,11,16,24
Insulin resistance is associated with increased
age. Aging leads to a reduction in lean body mass,
which contributes to insulin resistance; increasing
fat mass also increases insulin resistance.
7 Results
from the current study support that aging and in-
creasing body fat content are associated with
insulin resistance.
In this study, insulin-resistant subjects did not
have general adiposity, and BMI did not appear
to be related to insulin resistance, but central
adiposity and body fat content were significantly
correlated with insulin resistance. WC and body
fat content provided a better measure of visceral
adiposity than did BMI. We evaluated visceral
adiposity using WC or body fat content. It is a
limitation of our study that visceral fat was not
measured directly.
It has been reported that there is an adverse
relationship between insulin sensitivity and
hypertension.
5,25 In this study, insulin resistance
was not associated with diastolic blood pressure,
but was associated with higher systolic blood
pressure. Previous studies have reported that
insulin resistance is associated with elevated
triglycerides and lower HDL cholesterol levels in
type 2 diabetic subjects.
6,7,26 However, the present
study shows no difference in lipid profiles. In
general, during the process of atherosclerosis,
which is partly involved in insulin resistance, the
systolic blood pressure is more elevated than the
diastolic blood pressure.
27 Thus, if insulin-resis-
tant subjects included in our study were in the
preliminary stages of atherosclerosis, differences
in diastolic blood pressure would not have been
as evident as differences in systolic blood pres-
sure. Similar reasoning could be applied to the
lack of dyslipidemia differences between the two
groups.
In addition, insulin resistance may influence not
only the lipid levels but also lipid profile patterns,
such as the HDL subfraction or the LDL size.
28
Thus, there could be changes in the HDL sub-
fraction or the LDL size, and no differences
between the lipid levels of the two groups. The
results of this study also imply that other factors,
such as hypertension, dyslipidemia, or β-cell
function, affect the clinical manifestations. These
factors might influence the clinical course of dia-
betes. The present study has some shortcomings
in terms of the evaluation of β-cell function,
which is an important aspect of pathogenesis, and
was evaluated by fasting or postprandial insulin
and C-peptide. The variation between individuals
and the dependency on blood glucose levels are
limitations to the clinical use of fasting or post-
prandial insulin and C-peptide,
29 and the results
of this study showed that hypertension and a
family history of cerebrovascular disease are more
prevalent in insulin-resistant patients. After ad-
justing for HbA1c, the insulin resistance, as as-
sessed by ISI, was strongly associated with age,
WC, and body fat content. When type 2 diabetic
patients demonstrated these clinical manifesta-
tions, they tended to be insulin resistant, and
therefore insulin sensitizers, rather than insulin
secretagogues, should be considered as elements
of the treatment regimen.
30,31 Based on the conclu-
sions of the U.K. Prospective Diabetic Study
(1998), the use of insulin sensitizers may prove
beneficial, because this aspect of treatment is
based on pathogenesis.
32 In practice, this means
that in terms of potential insulin-sensitizing a-
gents, therapies based upon metformin or thia-
zolidinedione, are more likely to produce a better
outcome in this insulin resistant group of patients
than are sulfonylureas. Clinical trial studies
should be conducted to investigate the merits of
this approach, with an emphasis on clinical out-
come.
In summary, we compared the clinical and
biochemical characteristics of insulin-sensitive and
insulin-resistant diabetic patients. Age, hyperten-
sion, central obesity, and poor glycemic control
were identified as clinical parameters of insulin
resistance in Korean type 2 diabetic patients.
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